Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinumtoxin A for emotional stabilization in borderline personality disorder
2015-000749-21Phase 2Completed
- Sponsor
- Medizinische Hochschule Hannover
- Start
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of botulinum toxin type A in borderline personality disorder (BPD), sponsored by Medizinische Hochschule Hannover. Primary endpoint: Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD). Started Dec 2015; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on 2015-000749-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000749-21.